.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Novartis
Baxter
Julphar
Argus Health
Teva
Federal Trade Commission
US Army
Healthtrust
Colorcon

Generated: December 15, 2017

DrugPatentWatch Database Preview

Amarin Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for AMARIN PHARMS, and what generic alternatives to AMARIN PHARMS drugs are available?

AMARIN PHARMS has two approved drugs.

There are twenty-five US patents protecting AMARIN PHARMS drugs and there have been two Paragraph IV challenges on AMARIN PHARMS drugs in the past three years.

There are one hundred and seven patent family members on AMARIN PHARMS drugs in forty countries and two supplementary protection certificates in one country.

Summary for Amarin Pharms

International Patents:107
US Patents:25
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-002Feb 16, 2017RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-002Feb 16, 2017RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for AMARIN PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
icosapent ethylCapsules500 mgVASCEPA8/29/2017
icosapent ethylCapsules1 gVASCEPA7/26/2016
icosapent ethylCapsules1 gVASCEPA1/15/2013

Non-Orange Book Patents for Amarin Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,680,144Methods of treating mixed dyslipidemia► Subscribe
8,613,945Stable pharmaceutical composition and methods of using same► Subscribe
9,138,415Stable pharmaceutical composition and methods of using same► Subscribe
9,060,982Stable pharmaceutical composition and methods of using same► Subscribe
6,384,077 Highly purified EPA for treatment of schizophrenia and related disorders► Subscribe
8,642,077Stable pharmaceutical composition and methods of using same► Subscribe
8,691,871Methods of treating mixed dyslipidemia► Subscribe
9,060,983Stable pharmaceutical composition and methods of using same► Subscribe
8,663,662Stable pharmaceutical composition and methods of using same► Subscribe
8,618,166Methods of treating mixed dyslipidemia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Amarin Pharms Drugs

Country Document Number Estimated Expiration
China104042617► Subscribe
South Korea20110110321► Subscribe
Canada2759176► Subscribe
Hong Kong1165698► Subscribe
New Zealand624963► Subscribe
South Korea101343249► Subscribe
Colombia6470838► Subscribe
Estonia04629► Subscribe
European Patent Office2596786► Subscribe
European Patent Office1148873► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Amarin Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0037Belgium► SubscribePRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
C0009Belgium► SubscribePRODUCT NAME: CONCENTRE A 85 % D'OMEGA POLYINSATURES; QUANTITE CORRESPONDANT A :; ESTERS ETHYLIQUES D'ACIDE EICOSAPENTAENOIQUE (EPA) ET D'ACIDE DOCOSAHEXAENOIQUE (DHA); ALPHA TOCOPHEROL; NAT. REGISTRATION NO/DATE: NL 20819 19951002; FIRST REGISTRATION:
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Boehringer Ingelheim
Novartis
Citi
Harvard Business School
Farmers Insurance
Julphar
QuintilesIMS
Daiichi Sankyo
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot